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Abstract
Background: TRP channels have been shown to be involved in tumour generation and malignant
growth. However, the expression of these channels in breast cancer remains unclear. Here we
studied the expression and function of endogenous TRPC6 channels in a breast cancer cell line
(MCF-7), a human breast cancer epithelial primary culture (hBCE) and in normal and tumour breast
tissues.
Methods: Molecular (Western blot and RT-PCR), and immunohistochemical techniques were
used to investigate TRPC6 expression. To investigate the channel activity in both MCF-7 cells and
hBCE we used electrophysiological technique (whole cell patch clamp configuration).
Results: A non selective cationic current was activated by the oleoyl-2-acetyl-sn-glycerol (OAG)
in both hBCE and MCF-7 cells. OAG-inward current was inhibited by 2-APB, SK&F 96365 and La3+.
TRPC6, but not TRPM7, was expressed both in hBCE and in MCF-7 cells. TRPC3 was only
expressed in hBCE. Clinically, TRPC6 mRNA and protein were elevated in breast carcinoma
specimens in comparison to normal breast tissue. Furthermore, we found that the overexpression
of TRPC6 protein levels were not correlated with tumour grades, estrogen receptor expression
or lymph node positive tumours.
Conclusion: Our results indicate that TRPC6 channels are strongly expressed and functional in
breast cancer epithelial cells. Moreover, the overexpression of these channels appears without any
correlation with tumour grade, ER expression and lymph node metastasis. Our findings support the
idea that TRPC6 may have a role in breast carcinogenesis.
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Background
Breast cancer has the highest incidence rate for cancer in
women in industrialized countries. Statistically, it is esti-
mated that one woman out of ten will develop breast can-
cer at some point in her life. Evidence is accumulating for
the role of ion channels in the development of cancer. The
most studied ion channels in breast cancer are firstly K+
channels, which are involved in proliferation, cell cycle
progression and migration [1-4], and secondly Na+ chan-
nels which correlate with invasion [5-7]. Apart from the
role of intracellular calcium in MCF-7 apoptosis [8], little
is known of Ca2+ homeostasis in breast cancer cells. The
first study reported by Strobl et al., [9], suggested that Ca2+
is necessary for the cell cycle progression in breast cancer
cells. Moreover, the early findings of Sergeev indicate that
voltage-insensitive channels and Ca2+ endoplasmic reticu-
lum stores are the principal pathways for Ca2+ entry in
MCF-7 breast cancer cell line [8,10]. Recently, Guo et al.,
[11], have reported that the inhibition of a voltage-inde-
pendent calcium channel induced growth inhibition and
apoptosis in breast cancer cells. However, until now, the
channel types involved in this cationic current have
remained unknown. Recent findings demonstrate that the
expression and/or activity of the TRP superfamily, have
been reported to be involved in colorectal, colon, thyroid,
breast, ovarian, pancreatic and prostate cancer [12,13].
Among these, prostate cancer has been the most studied
[12,14-17]. Indeed, TRPV6 is strongly expressed in
advanced prostate cancer, with no expression either in
healthy or in benign prostate tissues [17]. Moreover, the
TRPV6 expression correlates with the Gleason score [18],
and with aggressiveness [14,16,18]. Another type of TRP:
TRPM8 was detected at high levels in both benign prostate
hyperplasia and in prostate carcinoma cells, as well as at
low levels in normal (non-carcinoma) prostate epithelial
cells. According to these data, TRPM8 has recently been
proposed as a molecular target [13,19] and TRPV6 as a
general marker for neoplasma [15,20].
The TRPC subfamily, TRPC1 TRPC7, has mostly been
implicated in regulation by G-proteins and metabolites of
phosphoinositide hydrolysis. TRPC6 channels, known to
be activated by the phospholipase C (PLC) product, Dia-
cylglycerol (DAG) [21-24], is abundantly expressed and
plays an important role in lung tissues and in different
smooth muscle cell types [22,25-27].
TRPC6 was suggested as being the molecular correlate to
the α1-adrenoceptor-activated non-selective cation chan-
nel in vascular smooth muscle cells [24,28]. Moreover,
TRPC6 is also involved in some smooth and cardiac mus-
cle pathologies [27,29,30]. TRPC6 is also expressed in epi-
thelial human prostatic cancer cells and the Ca2+-entry via
this channel mediates the activation of calcineurin, which
in turn induces proliferation via its downstream NFAT
(nuclear factor of activated T-cells) transcription factors,
which are necessary and sufficient for the induction of
prostatic cancer cell proliferation [31].
Previously, we have reported that TRPC6 is expressed in
MCF-7 [32]. However, until now, little is known about the
relative expression of TRPC6 in normal and cancerous
breast cells.
The aim of this study is, on the one hand, to compare the
expression of TRPC6 in normal and cancerous human
breast tissues. On the other hand, we have sought to inves-
tigate the role of TRPC6 by using electrophysiological and
molecular techniques. To do this, we used breast tissue
specimens, primary cultures of human breast cancer epi-
thelial (hBCE) cells and MCF-7 cell line.
Methods
Cell culture
MCF-7 cells were cultured in Eagle's Minimum Essential
Medium (EMEM), supplemented with 5% foetal calf
serum (FCS), 2 mM L-glutamine, and 0.06 % Hepes
buffer, and maintained at 37°C in a humid atmosphere of
5% CO2 in air.
Immunohistochemistry
Normal and cancerous breast tissues were obtained from
fresh surgical specimens. Surgical consent forms
(approved by the University Hospital of Amiens) were
signed by the patients before surgery to allow the use of a
portion of the tissue for research purposes.
49 normal and cancer human breast specimens were
obtained from women having undergone operations at
the Amiens Hospital, France. Normal breast samples were
taken at a distance from the tumour. Regarding tumour
grade in the 49 invasive ductal breast carcinomas, 15 were
of Grade I (well-differentiated), 19 were of Grade II (mod-
erately-differentiated) and 15 were of Grade III (poorly-
differentiated). On diagnosis, 23 tumours presented
lymph-node metastasis.
Immunohistochemical studies were performed using the
indirect immuno-peroxidase staining technique on the
paraffin-embedded material with a Ventana ES automatic
analyzer (Ventana Medical Systems) and with a hematox-
ylin counterstain. Briefly, after blocking the endogenous
peroxidase by the I-View Inhibitor (Ventana), sections
were stained with an anti-TRPC6 antibody (Chemicon, 1/
300) for 32 min, washed, incubated with biotinylated
anti-rabbit IgG (I-View Biotin Ig, Ventana) for 8 min,
washed and exposed to streptavidine-peroxidase complex
(I-View SA-HRP, Ventana) for 8 min. DAB/H2O2 was
used as chromogen and the slides were then examined
under optical microscopy. Micrograph acquisitions wereBMC Cancer 2008, 8:125 http://www.biomedcentral.com/1471-2407/8/125
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performed by a camera connected to a Zeiss microscope
equipped with 20 × 0.85 objective lens.
Immunostaining levels in the tumour tissue were deter-
mined by subjective visual scoring of the brown stain, and
compared to the normal tissue. Scoring levels were: 0 =
absence of staining; 1 = weak staining intensity (equal to
normal tissue); 2 = moderate; 3 = strong staining inten-
sity. For the quantitative analysis, we report the percent-
age of cases presenting an overexpression of TRPC6
(scores 2 and 3).
Peptide blocking was performed as follows. The TRPC6
peptide (1 μg, Chemicon) was incubated with the primary
antibody (1 μg) for one hour at room temperature. The
complex was then applied to the sections in place of the
diluted primary antibody and staining was completed as
already described.
Primary culture
Portions of human breast cancerous tissues were placed in
transport medium and desegregated immediately or after
storage at 4°C for less than 6 h. The transport medium
contained RPMI 1640 medium, 100 U/ml penicillin, 0.1
mg/ml streptomycin, 2 mM glutamine, 10% FBS and
0.010 mg/ml insulin. Adipose or gross and necrotic mate-
rials were removed and the tissue minced using a scalpel
in phosphate buffer solution (PBS) pH 7.4 under sterile
conditions. Cancerous tissues were digested in transport
medium containing 1 mg/ml collagenase type I (Sigma,
France) and 100 U/ml hyaluronidase (Sigma, France)
overnight at 37°C. When digestion was completed, tissue
suspensions were centrifuged at 1000 rpm for 5 min and
the pellets resuspended in sterile PBS pH 7.4. The dis-
persed cell suspensions were centrifuged at 1000 rpm for
5 min and pellets resuspended in 20% FBS growth
medium (RPMI 1640 medium, 100 U/ml penicillin, 0.1
mg/ml streptomycin, 2 mM glutamine, 0.005 mg/ml
insulin, 5 ng/ml epidermal growth factor (EGF), 0.5 μg/
ml hydrocortisone, 5 μg/ml transferrin, 0.1 μM isoproter-
enol, 0.01 μM ethanolamine, 0.01 μM  o-phos-
phoetanolamine) and seeded in culture flasks (Nunc,
Poly Labo, Strasbourg, France) and kept at 37°C in a
humidified incubator in a 95% air 5% CO2 atmosphere.
Each sample was analyzed by immuno-fluorescence stain-
ing to verify the pan-cytokeratin expression, which is an
epithelial marker.
We used specimens from invasive ductal breast carcino-
mas and clinical tumour (Grade II), from patients having
undergone a mastectomy. None of the patients had a his-
tory of chemotherapy and/or anti-estrogens therapy. The
absence of normal epithelial cells was confirmed by inde-
pendent histologic and anatomopathologic analysis.
Electrophysiology
For electrophysiological analysis, cells were cultured in 35
mm Petri dishes at a density of 5.104 cells 2 days before
patch clamp experiments. Currents were recorded in volt-
age-clamp mode, using an Axopatch 200 B patch-clamp
amplifier (Molecular devices) and a Digidata 1200 inter-
face (Molecular device). PClamp software (v. 6.03, Molec-
ular device) was used to control voltage, as well as to
acquire and analyze data. The whole-cell mode of the
patch-clamp technique was used with 3–5 MΩ resistance
borosilicate fire-polished pipettes (Hirschmann®,
Laborgerate). Seal resistance was typically in the 1–5 GΩ
range. Whole cell currents were allowed to stabilize for 5
min before being measured. Cells were allowed to settle in
Petri dishes placed at the opening of a 250 μm-inner
diameter capillary for extra-cellular perfusions. The cell
under investigation was continuously superfused with
control or test solutions. All electrophysiological experi-
ments were performed at room temperature.
Total RNA isolation and reverse transcription of RNA
Total RNA from MCF-7 cells and primary culture cells was
extracted by the Trizol-phenol-chloroforme (Sigma
Aldrich) procedure, including DNAse I treatment (0.2 U/
μl, 30 min at 37°C, Promega). Total RNA was then
reverse-transcribed into cDNA using oligodT primers and
SuperScript™ II Reverse Transcriptase (Invitrogen).
RNA isolation of normal and tumour tissues was per-
formed using the RNAeasy Mini Kit (Qiagen). Pieces of
tissue (20 mg) were placed in a lysis buffer and homoge-
nized using a Polytron homogenizer (PRO-200, Fisher
Bioblock Scientific), and total RNA was isolated according
to the manufacturer s standard protocols and used (1 μg)
for first-strand cDNA synthesis with oligodT primers and
MultiScribeTM Reverse Transcriptase (Applied Biosys-
tems).
Qualitative and semi-quantitative PCR
Sense and antisense PCR primers specific to TRPC3,
TRPC6, TRPC7 channels, β-actin and cytokeratin 19
(CK19) were used (see Table 1: primers for PCR experi-
ments). PCR reactions were carried out on a iCycler ther-
mal cycler (Biorad) using Taq DNA polymerase
(Invitrogen) using the following parameters: denatura-
tion at 94°C for 30 s, annealing at 58°C for 30 s, and
extension at 72°C for 40 s. A total of 30 cycles for actin
and 40 cycles for the other primers were performed, fol-
lowed by a final extension at 72°C for 5 min. PCR prod-
ucts were analyzed by electrophoresis with 1.5% agarose
gel and visualized by ethidium bromide staining.
For the semi-quantitative experiments, 40 cycles, 25 cycles
and 35 cycles were performed for TRPC6, β-actin and
CK19 respectively. After agarose gel electrophoresis, PCRBMC Cancer 2008, 8:125 http://www.biomedcentral.com/1471-2407/8/125
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products were quantified using Quantity One software
(Biorad) and expressed as the ratio of TRPC6 on β-actin or
CK19 referent genes. CK19 has been shown to be specific
to breast epithelial cells, both normal and malignant [33].
Western Blotting
Prostate human cancer cell line (LNCaP), MCF-7 cells and
primary culture cells were lysed for 30 min on ice in RIPA
buffer (1% triton ×100, 1% Na deoxycholate, 150 mM
NaCl, 10 mM PO4Na2/K pH 7.2) supplemented with
Sigma P8340 inhibitor cocktail, 2 mM EDTA and 5 mM
Na orthovanadate. After centrifugation at 13000 rpm, the
proteins in the supernatant were quantified using the BCA
method (Biorad).
Breast tissue proteins were extracted using the WCE buffer
(Whole Cell Extract : 150 mM NaCl, 50 mM Tris HCl
pH7.5, 1% NP40) supplemented with Sigma P8340
inhibitors cocktail, 0.1% SDS and 1 mM Na orthovanad-
ate. After 1 hour in lysis buffer at 4°C, tissues were
homogenized using a Polytron homogenizer (PRO-200,
Fisher Bioblock Scientific) and frozen 20 min at -80°C.
After centrifugation at 13000 rpm, the proteins in the
supernatant were quantified using the BCA method (Bio-
rad).
Equal amounts of each protein sample (15–20 μg) were
separated by electrophoresis on SDS-PAGE and blotted
onto nitrocellulose membrane (Amersham). Blots were
incubated with antibodies raised against TRPC6 (1/300,
Chemicon) or β-actin (1/1000, Santa Cruz) and devel-
oped with the enhanced chemiluminescence system (ECL,
Amersham) using specific peroxidase-conjugated anti-IgG
secondary antibodies. Peptide blocking was performed as
described in the immunohistochemistry section.
Solutions
External and internal solutions had the following compo-
sitions (in mM): External: NaCl 140, KCl 5, MgCl2 2,
CaCl2 2, HEPES 10 and glucose 5 at pH 7.4 (NaOH).
Internal: CsCl 140, CaCl2 5, ATP-K2 1, HEPES 10, EGTA
10, MgCl2 2, at pH 7.2 (CsOH). The [Ca2+]i was clamped
to 85 nM and calculated with WebMaxC v2.1 (please see
Availability & requirements section below).
Extracellular and intracellular osmolarity measured with a
freezing-point depression were 300 mOs and 292 mOs
respectively. In order to completely block K+ channels, we
added TEA at 5 mM to the extracellular medium. 2-APB,
SK&F 96365 and OAG (Sigma, France) were dissolved in
DMSO. Final concentrations were obtained by appropri-
ate dilution in an external control solution. The final
DMSO concentration was < 0.1%.
Statistical analysis
Results were expressed as mean ± S.E. The Student s t test
was used to compare the relative TRPC6 transcripts in nor-
mal and cancer tissues. P < 0.05 was considered as signif-
icant. Immunostaining in the epithelial compartment of
tumour tissues compared to normal tissues was scored vis-
ually as equal expression or overexpression of TRPC6. χ2
tests were used in GraphPad Software to estimate the cor-
relation between TRPC6 overexpression and clinical char-
acteristics of the carcinoma tissues. A correlation was
considered significant when P < 0.05.
Results
OAG induced a non-selective cationic current in the MCF-
7 breast cell line
We have previously reported that TRPC6 is the detectable
member of the store-independent TRPC channels
expressed in breast cancer cells [32]. Recent studies have
revealed that the permeant DAG analogue, OAG can stim-
ulate an inward current in cancerous epithelial cells [31].
We recorded OAG-induced channel activity in MCF-7
cells using the whole cell patch clamp configuration,
replacing K+ with Cs+ to block K+ channels and using a
high [Ca2+]i to prevent the passive intracellular Ca2+ store
depletion that could lead to activation of store operated
channels (SOC, Isoc current) (Fig. 1). An application of 50
μM of OAG to the bath induced a linear current in MCF-7
cells. The current/voltage dependence of this OAG-
Table 1: Primers for PCR experiments
Gene Accession n° Primer Sequence (5-3) Predicted Size, bp
hTRPC3 NM003305 Sense GGAAAAACATTACCTCCACCTTTCA
Antisense CTCAGTTGCTTGGCTCTTGTCTTCC 383 pb
hTRPC6 NM 004621 Sense GAACTTAGCAATGAACTGGCAGT 625 pb for TRPC6
Antisense CATATCATGCCTATTACCCAGGA 277 pb for TRPC6γ
hTRPC7 NM 020389 Sense GTCCGAATGCAAGGAAATCT
Antisense TGGGTTGTATTTGGCACCTC 477 pb
hβ-actin NM 001101 Sense CAGAGCAAGAGAGGCATCCT
Antisense ACGTACATGGCTGGGGTG 210 pb
hCK19 NM 002276 Sense GATTGCCACCTACCGC
Antisense CCATCCCTCTACCCAG 136 pbBMC Cancer 2008, 8:125 http://www.biomedcentral.com/1471-2407/8/125
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induced current displayed both inward and outward cur-
rents (Fig. 1A). This current revealed a pattern of a non-
selective cation current (Fig. 1A) with a reversal potential
close to 0 mV (7.2 ± 1.4, n = 12). The average density of
OAG-induced current measured at -100 mV varied
between -25 and -12.5 pA/pF with a mean of -18.3 ± 2.7
pA/pF (n = 10). The time course for OAG-induced current
at -100 mV revealed an inward current which reached a
peak in about 3 min (Fig. 1B).
Pharmacological properties of the OAG-induced current
A number of pharmacological agents have been used to
characterize DAG-induced currents or Ca2+ entry path-
ways in a variety of cell types [34]. Here we show that 2-
APB reduced and completely inhibited the OAG-induced
current in MCF-7 cells when used at 50 μM and 100 μM
respectively (Fig. 1CD, n = 4), and this effect was totally
reversed after washout (Fig. 1D). Moreover, the OAG-sen-
sitive current was also completely inhibited by 100 μM
La3+ (Fig. 1CD, n = 6) and by 10 μM SK&F 96365 (Fig. 1E,
n = 3).
OAG also induced a cationic current in primary epithelial 
breast human cells (hBCE)
A typical OAG-induced current could also be recorded in
hBCE cells. A representative example is shown in Fig. 2AB.
The average density of the OAG-induced current meas-
ured at -100 mV varied between -50 and -20.6 pA/pF with
a mean of -34.3 ± 4.6 pA/pF (n = 7). The current that we
recorded had a Erev about 0 mV (6.0 ± 2.4 mV, (n = 4)) and
Electrophysiological and Pharmacological characterisation of the OAG-induced current in MCF-7 cell line Figure 1
Electrophysiological and Pharmacological characterisation of the OAG-induced current in MCF-7 cell line. A) 
Typical current trace recorded during the current induced by 50 μM OAG. The holding potential was -40 mV and 400 ms volt-
age ramps were applied from -100 mV to +100 mV. The reversal potential (Erev) of the currents recorded was about 0 mV. B) 
Time course development of OAG-inward currents (measured at -100 mV) in a representative MCF-7 cell bathed in external 
control medium. C-D) 2-APB (50 and 100 μM) and La3+ (100 μM) effects on time course of OAG-induced current recorded at 
-100 mV. E) The extracellular perfusion of SK&F 96365 (10 μM) completely inhibited the current induced by OAG (50 μM).
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was again reduced by 50 μM 2-APB (Fig. 2C, n = 6) or
completely blocked by 100 μM 2-APB (Fig. 2D, n = 6) and
by La3+ (100 μM, n = 6) (Fig. 2CE).
Expression of OAG-gated TRP channels in human breast 
cancer epithelial cells
TRPC3, TRPC6 and TRPC7 are reported to be directly
gated by DAG and OAG [23,35]. Therefore, in order to
determine potential candidates for the OAG-coupled cati-
onic channel(s) in hBCE, we used RT-PCR to analyse the
expression of the specific transcripts for the human iso-
forms of these DAG-gated TRP members in these cells. As
expected, MCF-7 cells expressed only TRPC6 while hBCE
expressed both TRPC6 and TRPC3 transcripts (Fig. 3A),
whereas TRPC7 was undetectable (Fig. 3B) in either cell.
The prostate cancer cell line (LNCaP) was used as a posi-
tive control for TRPC3 and a negative one for TRPC6.
Indeed, it has been reported that LNCaP cells express
TRPC3 but not TRPC6 [36]. Moreover, both MCF-7 and
hBCE cells express a TRPC6γ splice variant (Fig. 3A).
TRPC6 is expressed in breast tumour tissues
No data are available on the expression of TRPC6 in
human carcinoma tissue. Fig. 4 shows the expression of
the transcripts for the TRPC6 in human breast tissue (Fig.
4A). Moreover, we also observed the expression of the
TRPC6γ splice variant. Using Western blotting, we found
that the TRPC6 proteins were expressed in breast carci-
noma (Fig. 4B). There was no band when we omitted the
primary antibody or when we blocked the TRPC6 anti-
body with the TRPC6 peptide (Fig. 4B). Moreover, TRPC6
is also expressed at a protein level both in MCF-7 cells and
in hBCE (Fig. 4C). Again, there was no band when we
used lysate from LNCaP (Fig. 4C).
OAG mediated an inward cationic current in primary hBCE Figure 2
OAG mediated an inward cationic current in primary hBCE. A) Current-potential relationship in the absence and 
presenceof OAG (50 μM). The holding potential was -40 mV and 400 ms voltage ramps were applied from -100 mV to +100 
mV. B) Time course of the inward whole-cell membrane current activated by OAG (50 μM). C-E) Effects of the common cati-
onic channels inhibitors, 2-APB 50 μM (C), 100 μM (D), and 100 μM La3+ (C, E) on the amplitude of OAG-induced inward cur-
rent measured at -100 mV.
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Overexpression of TRPC6 in breast adenocarcinoma
Immunohistochemical analysis was performed on 49 nor-
mal tissues and ductal breast carcinomas. Normal breast
specimens were obtained from mammectomy specimens,
at a distance from the tumour. High expression of TRPC6
was detected in tissue of breast cancer and small or nega-
tive expression was detected in normal tissue. The fre-
quency of TRPC6 expression in breast cancer averaged
73.4% (36/49) of the cases studied. Fig. 5A shows repre-
sentative positive expression of neoplastic tissue of breast
cancer. The staining of breast adenocarcinoma (a2) dem-
onstrated a stronger positive reaction than its normal
counterpart (a1). There was no or little staining when the
primary antibody was omitted (b1, b2), or after preincu-
bation of TRPC6 peptide with the primary antibody (c1,
c2).
Using semi-quantitative PCR, we analyzed TRPC6 mRNA
expression in tumour and normal tissues from 3 individ-
ual patients. As shown in Fig. 5B &5C, TRPC6 mRNA
expression was generally higher in the tumour tissues after
normalization both with CK19 or β-actin (P < 0.05).
We next compared the expression of TRPC6 with LNM,
estrogen receptor (ER) expression, and tumour grade. A
quantitative analysis, using χ2 statistical test, of the results
obtained is reported in Table 2. The TRPC6 protein
expression was similar in tumour tissues associated (78%,
n = 23) or not associated (69%, n = 26) with LNM. Non
significant differences in the TRPC6 expression were also
found with estrogen receptor expression. Regarding
TRPC6 channel protein expression with tumour grade, we
found that TRPC6 was expressed in 73.3% and 68.4% of
grade I and grade II respectively, and increased to 80% in
grade III.
Discussion
Many recent works report the involvement of TRP chan-
nels in cancer. Our results point towards an aberrant
expression of TRPC6 channels in breast cancer. This study
shows that TRPC6 is expressed in both the MCF-7 breast
cancer cell line and in the primary cultures of breast cancer
epithelial cells. TRPC6 appears to be functional both in
MCF-7 and in hBCE. Moreover, TRPC6 is highly expressed
in breast carcinoma and is not correlated with estrogen
receptor expression, tumour grade, or LNM.
Our results demonstrate that the OAG-activated cationic
channels both in hBCE and MCF-7 cells share the same
electrophysiological (lack of voltage dependence, and a
similar reversal potential) and pharmacological proper-
ties (sensitivity to 2-APB, La3+ and SK&F 96365). The
TRPC candidates activated by OAG are limited to TRPC3,
TRPC6, and TRPC7 [23,35]. TRPC6 is expressed at mRNA
and protein levels both in MCF-7 and hBCE cells. Moreo-
ver, TRPC3 is also expressed in hBCE and its expression
seems weak compared to that of the TRPC6 (Fig. 3A).
However, the findings that hBCE cells express both TRPC3
and TRPC6, may indicate that the OAG-gated cationic
channel(s) in theses cells are probably heterotetramultim-
ers that include TRPC6/TRPC3.
We also extended our studies to examine TRPC6 expres-
sion at the protein levels in breast cancer tissues. No spe-
cific bands were obtained when we performed Western
blot analyses: (i) on lysates from LNCaP, used as negative
control [36], (ii) by omitting the primary antibody and
(iii) by blocking the primary antibody with the TRPC6
peptide. In contrast, both tumour, MCF-7 and hBCE
lysates produced a 97 kDa band corresponding to the
expected size of full length TRPC6. Moreover, no other
Analysis of TRPC3, TRPC6 and TRPC7 mRNA expression in  MCF-7 and hBCE cells Figure 3
Analysis of TRPC3, TRPC6 and TRPC7 mRNA 
expression in MCF-7 and hBCE cells. RT-PCR analysis 
of the expression of human TRPC3, TRPC6 (A), and TRPC7 
(B) transcripts in hBCE and MCF-7 cells. The PCR products 
were obtained using the primers described in Table 1. Rat 
brain and the human prostate cancer epithelial cell line 
(LNCaP) were used as positive controls for the detection of 
TRPC7, and TRPC3 respectively. LNCaP was also used as 
negative control for TRPC6.
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band was observed, suggesting that TRPC6γ splice variant
is not translated into protein.
A growing number of studies demonstrate a close correla-
tion between an overexpression of TRP channels particu-
larly of the TRPV6 and TRPM8 families and the
development of cancer [13,16]. However, little is known
about the expression pattern of TRPC6 or its possible role
in the development of cancer, and breast cancer in partic-
ular. To our knowledge, there is only one study which
shows the involvement of the TRPC6 channels in the pro-
liferation of epithelial human prostate cancer cells in pri-
mary culture [31]. Our results clearly show that in healthy
breast tissues low levels of TRPC6 are detected in all cases
determined. In contrast, the breast carcinoma tissue spec-
imens revealed a significant overexpression of TRPC6.
Moreover, TRPC6 are expressed and functional in the
MCF-7 cell line and in hBCE. In vivo, the upregulation of
TRPC6 was much more clearly demonstrated in cardiovas-
cular pathologies such as hypertension, hypertrophy and
increased endothelial permeability [27,29,30].
Expression of TRPC6 in human breast cancer Figure 4
Expression of TRPC6 in human breast cancer. A) Expression pattern of TRPC6 mRNA. The PCR products were 
observed in 3 human tumour breast tissues. A representative Western blot of TRPC6 (around 97 kDa) was performed on 
breast tumour tissues (B), MCF-7 and hBCE cells (C). TRPC6 Ab : TRPC6 antibody; (-) incubation of tumour tissue protein 
lysates with only the second antibody; (+ peptide) protein lysates are incubated with a mixture of TRPC6 antibody and 
TRPC6 peptide. Protein lysates from LNCaP cells were used as negative control (C).
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Few studies have compared the ionic channel expression
with the tumour grade, LNM and receptor expression sta-
tus. Indeed, GIRK1 was overexpressed in primary invasive
breast carcinoma and correlate with LNM [37]. Pardo s
group has found there were no correlations between Eag1
expression and age, grade and site of tumour of soft tissue
sarcoma [38]. Similar results on Eag1 expression are
found in colorectal cancer [39]. In line with these studies,
we show that the TRPC6 protein levels are increased in
breast tumour tissues but were not correlated either with
tumour grade, ER or LNM.
Evidence indicates a crucial role for TRP channels in regu-
lating both cell growth and cell death. Recently, it was
reported that TRPV6 induced cell proliferation and took
part in the resistance to apoptosis in the prostate human
LNCaP cancer cells [40]. TRPC6 has been reported to be
involved in primary epithelial prostate human cell prolif-
eration induced by the α1-adrenergic receptors [31].
Breast cancer cells, including MCF-7 express G protein-
coupled receptors including α1-adrenergic receptors [41].
We can thus speculate that the entry of Ca2+ through
TRPC6 channel may induce breast cancer cell prolifera-
tion in response to G protein-coupled receptor signalling.
More studies are needed to determine the involvement of
TRPC6 in breast cell proliferation.
Conclusion
Our data demonstrate that TRPC6 is expressed and func-
tional in breast cancer epithelial cells. Moreover, this
Overexpression of TRPC6 in breast adenocarcinoma Figure 5
Overexpression of TRPC6 in breast adenocarcinoma. A) Normal (a1) and tumour (a2) breast tissues show a respec-
tively weaker and a stronger staining when incubated with TRPC6 antibody. (b1) and (b2) are the same field showing no stain-
ing when the primary antibody was omitted. TRPC6 staining of normal (c1) and tumour (c2) breast tissue was blocked by the 
preincubation of TRPC6 peptide with the primary antibody. (magnification, × 200). B) TRPC6 transcripts were detected in 
breast tissues (N = normal, T = tumour) by semi-quantitative PCR using TRPC6, β-actin, or CK19 primers. C) Relative TRPC6 
expression in breast cancer tissues. TRPC6 mRNA was quantified using Quantity One software and normalized to β-actin or 
CK19 expression. Data are presented as the average of duplicate experiments on three distinct patients (* P < 0.05).
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channel is overexpressed in tumour tissues without any
correlation with tumour grade, ER expression and lymph
node metastasis.
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